# UNITED STATES <br> SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

## Form 8-K

## CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): 02/25/2010

## Dynavax Technologies Corporation

(Exact name of registrant as specified in its charter)
Commission File Number: 001-34207
Delaware
(State or other jurisdiction of
incorporation)

33-0728374
(State or other jurisdiction of
(IRS Employer incorporation)

Identification No.)
2929 Seventh Street, Suite 100
Berkeley, CA 94710-2753
(Address of principal executive offices, including zip code)
(510) 848-5100
(Registrant s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form $\mathbf{8 - K}$ filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Edgar Filing: DYNAVAX TECHNOLOGIES CORP - Form 8-K

## Item 8.01. Other Events

On February 25, 2010, Dynavax Technologies Corporation (Dynavax) issued a press release titled "Dynavax Selects Clinical Candidate in Universal Flu Vaccine Program." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

## Item 9.01. Financial Statements and Exhibits

(d) Exhibit

## Exhibit No. Description

99.1 Press Release, dated February 25, 2010, titled "Dynavax Selects Clinical Candidate in Universal Flu Vaccine Program."

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dynavax Technologies Corporation

Date: February 25, 2010
By: /s/ Michael S. Ostrach

Michael S. Ostrach
Vice President

## EXHIBIT INDEX

## Exhibit No. Description

